Close
Help
signup_email_alerts
Need Help?



Triptans in the Treatment of Migraine

Submit a Paper


Libertas Analytics


1790 Article Views

Publication Date: 01 Jul 2009

Journal: Clinical Medicine Insights: Therapeutics

Citation: Clinical Medicine: Therapeutics 2009:1 711-713

CMIt journal

517,286 Article Views

6,291,447 Libertas Article Views

More Statistics

Baburhan Guldiken

Trakya University Medical Faculty, Department of Neurology, Edirne,Turkey.

Abstract

Migraine is a neurovascular disease, which pathogenesis is still unclear. It causes a severe headache and a substantial financial loss due to absenteeism, therefore, its effective treatment is particularly valuable. Triptans, selective 5HT1B and D receptor agonists, are effective treatment choices of acute migraine attacks. Migraine patients, who bear special conditions such as hypertension, hepatic or renal impairment, constitute a special subgroup of patients whose treatment with triptans has to be individually arranged. The review of Kalanuria and Peterlin, regarding the metabolism and efficacy of zolmitriptan in the abortive treatment of migraine, highlights many details of the use of zolmitriptan in migraine patients.


Post a Comment

x close

Discussion Add A Comment
No comments yet...Be the first to comment.


share on

Our Service Promise

  • Prompt Processing (Less Than 3 Weeks)
  • Fair & Comprehensive Peer Review
  • Professional Author Service
  • Leading Editors in Chief
  • Extensive Indexing
  • High Readership & Impact
  • What Our Authors Say

Quick Links

Follow Us We make it easy to find new research papers. RSS Feeds Email Alerts Twitter

BROWSE CATEGORIES
Our Testimonials
As the Editor-in-Chief of Clinical Medicine Insights: Trauma and Intensive Medicine, I experience an outstanding professional and timely support by the publisher, Libertas Academica, in all editorial matters.
Dr Philip F. Stahel (Denver Health Medical Center, University of Colorado Denver, School of Medicine, Denver, CO, USA) What our authors say